万达生物制药 VNDA 深 沪
已收盘 10-10 16:00:00 美东时间
5.31
-0.140
-2.57%
华盛通- 最 高5.52
- 今 开5.52
- 成交量 55.70万股
- 最 低 5.26
- 昨 收 5.45
- 总市值 3.14亿
- 52周最高 5.59
- 市盈率 静 --
- 换手率 0.94%
- 52周最低 3.8092
- 委 比 -39.49%
- 总股本 5908.91万
- 历史最高 33.44
- 量 比 0.81
- 振 幅 4.77%
- 历史最低 2.92
- 每 手 1
- 风险率 0.29%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Vanda Pharmaceuticals Reaches Agreement with FDA
Vanda ( ($VNDA) ) has issued an update. On October 1, 2025, Vanda Pharmaceutica...
10-02 05:27
Vanda Pharmaceuticals Announced The Publication Of An Article Titled "Melatonin Agonist Tasimelteon Improves Sleep In Patients With Primary Insomnia: A Multicenter, Randomized, Double-blind, Placebo-Controlled Trial" In PLOS One, A Leading Open-Access Journal
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced the publication of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial" in PLOS One, a leading open-access journal.1
09-25 20:08
Vanda Pharmaceuticals gets FDA orphan drug status for VGT-1849B
Vanda Pharmaceuticals (NASDAQ:VNDA) said that the U.S. FDA has granted orphan drug designation for its experimental drug candidate, VGT-1849B, for the treatment of polycythemia vera. With its orphan d...
08-28 22:08
Vanda asks FDA's Makary to review approval of Hetlioz generics
Vanda Pharmaceuticals (NASDAQ:VNDA) has formally asked U.S. FDA Commissioner Marty Makary to review the recently retired director of the Center for Drug Evaluation and Research's decision to uphold th...
08-22 05:35
Vanda Wins Major Court Battle For Jet Lag Drug, Forcing FDA To Revisit Rejection
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that it secured a landmark victory over the U.S. Food and Drug Administration (FDA) in its longstanding dispute with the agency regarding the approvability
08-18 19:08
中信证券：首予阜博集团“买入”评级 目标价8港元 看好全球维持版权保护长期需求
中信证券发布研报称，看好阜博集团（03738）投资价值公司，首次覆盖，给予“买入”评级。预计公司2025-2027年收入分别为29.79/37.38/47.1...
08-14 15:07
Vanda Pharmaceuticals Affirms FY2025 Sales Guidance of $210.00M-$250.00M vs $227.72M Est
Vanda Pharmaceuticals (NASDAQ:VNDA) affirms FY2025 sales outlook from $210.00 million-$250.00 million to $210.00 million-$250.00 million vs $227.72 million estimate.
07-31 19:37
Vanda Pharma Q2 EPS $(0.46) Misses $(0.36) Estimate, Sales $52.59M Miss $54.60M Estimate
Vanda Pharma (NASDAQ:VNDA) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.36) by 28.85 percent. This is a 475 percent decrease over losses of $(0.08) per share from the
07-31 19:36
Earnings Scheduled For July 31, 2025
Companies Reporting Before The Bell • Vanguard Extended Duration Treasury ETF (...
07-31 16:32
Here are the major earnings before the open Thursday
Major earnings expected before the bell on Thursday include: AbbVie (OTC:ABBY) Bristol-Myers Squibb Company (BMY) Mastercard Incorporated (MA) CVS Health Corporation (CVS) Shell plc (SHEL) Other earni...
07-31 06:00
